<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="at: [[inbox]]
Gastroenterology - Inflammatory Bowel Disease - Fast Facts | NEJM Resident 360 Inflammatory bowel disease (IBD) describes a range of idiopathic, chronic inflammatory diseases of the gastrointestinal (GI) tract."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Gastroenterology - Inflammatory Bowel Disease - Fast Facts | NEJM Resident 360"><title>Gastroenterology - Inflammatory Bowel Disease - Fast Facts | NEJM Resident 360</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.02120ee5abce9b994b1487466af3b5e4.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.2fa0b17fd062191acb59f3585f810af7.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=ÊêúÂ∞ã placeholder="Ë´ãËº∏ÂÖ•ÂÉèÊòØÔºöhypertension ‰πãÈ°ûÁöÑ‰æÜÁúãÊ≤íÊúâÊ≤í‰ªÄÈ∫ºÊúâË∂£ÁöÑüé≥"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>Ëú•Ëú¥Ëä±Âúíü¶éüå±ü™¥üå≤</a></h1><div class=spacer></div><div id=search-icon><p>ÊêúÂ∞ã</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">ÊêúÂ∞ãÂúñÁ§∫</title><desc id="desc">ÊâìÈñãÊêúÂ∞ãÂúñÊ®ô</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Êòé‰∫ÆÊ®°Âºè</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>ÈªëÊöóÊ®°Âºè</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Gastroenterology - Inflammatory Bowel Disease - Fast Facts | NEJM Resident 360</h1><p class=meta>ÊúÄÂæåÊõ¥Êñ∞Êñº
Feb 23, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Gastroenterology%20-%20Inflammatory%20Bowel%20Disease%20-%20Fast%20Facts%20%20NEJM%20Resident%20360.md rel=noopener>ü™ö Á∑®ËºØÂéüÂßãÊñá‰ª∂</a></p><ul class=tags></ul><p>at: <a class="internal-link broken">inbox</a></p><a href=#gastroenterology---inflammatory-bowel-disease---fast-facts--nejm-resident-360><h1 id=gastroenterology---inflammatory-bowel-disease---fast-facts--nejm-resident-360><span class=hanchor arialabel=Anchor># </span>Gastroenterology - Inflammatory Bowel Disease - Fast Facts | NEJM Resident 360</h1></a><p>Inflammatory bowel disease (IBD) describes a range of idiopathic, chronic inflammatory diseases of the gastrointestinal (GI) tract. Patients with IBD are usually managed as outpatients but can present with severe disease and complications. Although the etiology of IBD is unknown, it is likely a combination of genetic, immunologic, and environmental factors. In this section, we review the three primary subtypes of IBD:</p><ul><li><p><strong>Crohn disease (CD)</strong> involves any part of the GI tract; classically, the mucosa of the bowel is ‚Äúcobblestoned‚Äù in appearance. CD is a transmural disease involving the entire wall of the bowel. Histologically, granulomas may occur but are not required to make the diagnosis. Perianal disease is also common in CD.</p></li><li><p><strong>Ulcerative colitis (UC)</strong> involves only the colon (large bowel); UC may start in the rectum as proctitis and spread proximally to involve the entire colon (pancolitis). Rectal bleeding and diarrhea are typical presenting symptoms. Histologically, UC is a mucosal disease.</p></li><li><p><strong>Indeterminate colitis</strong> includes features of both UC and CD (up to 15% of all cases).</p></li></ul><a href=#clinical-features><h3 id=clinical-features><span class=hanchor arialabel=Anchor># </span>Clinical Features</h3></a><p>Clinical features of IBD depend on the areas of the GI tract that are affected, the extent of disease, and the severity of the inflammatory process. However, most patients with IBD present with abdominal pain and diarrhea, with or without blood. Patients with proctitis may report constipation and tenesmus. Patients may also present with systemic symptoms (e.g., low-grade fever, reduced appetite, and unintentional weight loss).</p><ul><li><p><strong>Crohn disease:</strong> Patients with CD may also present with GI fistulas, characterized by abnormal tracts between adjacent loops of bowel (enteroenteric fistula),¬†between intestine and bladder (enterovesical), the intestine and abdominal wall (enterocutaneous), or the intestine and the area around the anus and buttocks (perianal).</p></li><li><p><strong>Ulcerative colitis:</strong> A small proportion of patients with UC present with catastrophic manifestations such as toxic megacolon (transverse or right colon diameter >6 cm) or catastrophic hemorrhage.</p></li></ul><p>Differentiating between CD and UC has important clinical implications, particularly with regards to treatment and follow-up. The following table summarizes the key clinical differences:</p><a href=#key-clinical-differences-between-crohn-disease-and-ulcerative-colitis><h3 id=key-clinical-differences-between-crohn-disease-and-ulcerative-colitis><span class=hanchor arialabel=Anchor># </span>Key Clinical Differences Between Crohn Disease and Ulcerative Colitis</h3></a><table><thead><tr><th>Clinical Feature</th><th>Crohn Disease</th><th>Ulcerative Colitis</th></tr></thead><tbody><tr><td>Bright blood in stool</td><td>Sometimes</td><td>Yes</td></tr><tr><td>Mucus</td><td>Sometimes</td><td>Yes</td></tr><tr><td>Systemic symptoms</td><td>Frequently</td><td>Sometimes</td></tr><tr><td>Pain</td><td>Frequently</td><td>Sometimes</td></tr><tr><td>Abdominal mass</td><td>Sometimes</td><td>Rarely</td></tr><tr><td>Perianal disease</td><td>Yes</td><td>No</td></tr><tr><td>Fistulas</td><td>Yes</td><td>No</td></tr><tr><td>Small-bowel obstruction</td><td>Yes</td><td>No</td></tr></tbody></table><p><strong>Extraintestinal manifestations (EIMs) associated with IBD:</strong></p><ul><li><p><strong>Eyes:</strong></p><ul><li><p>Episcleritis is more common in CD and usually does not require specific treatment other than that for IBD.</p></li><li><p>Scleritis can cause visual impairment and requires disease-specific treatment and topical steroids.</p></li><li><p>Uveitis is less common than episcleritis and requires prompt treatment with topical and systemic glucocorticoids to prevent blindness.</p></li></ul></li><li><p><strong>Mouth:</strong></p><ul><li><p>aphthous ulcers</p></li><li><p>gingivitis</p></li></ul></li><li><p><strong>Joints:</strong> Seronegative peripheral and axial arthropathies. Arthritis in IBD has been classified into two types:</p></li><li><ul><li><p>type 1: pauciarticular (affects less than five joints and often involves large joints)</p></li><li><p>type 2: polyarticular (usually affects at least five small joints)</p></li></ul></li><li><p><strong>Skin:</strong></p><ul><li><p>Pyoderma gangrenosum is characterized by deep ulcers that involve the low anterior leg and occasionally the arm. It affects 5% of UC cases and 1% of CD cases and is more likely to develop in patients with severe disease and colonic involvement. The condition may resolve with IBD treatment, but surgical debridement may be required in severe cases.</p></li><li><p>Erythema nodosum is characterized by tender, red nodules on the legs and occasionally arms. Although it can affect patients with UC and CD, it is more prevalent in females and patients with CD.</p></li></ul></li></ul><p>View an interactive summary¬†of EIM of IBD.</p><p>Certain EIMs (e.g., pauciarticular arthritis, oral aphthous ulcers, erythema nodosum, and episcleritis) are more prevalent in patients with increased intestinal disease activity and improve with IBD treatment. However, the course of other EIMs (e.g., ankylosing spondylitis and uveitis) is independent of IBD disease activity.</p><a href=#pyoderma-gangrenosum-in-ulcerative-colitis><h3 id=pyoderma-gangrenosum-in-ulcerative-colitis><span class=hanchor arialabel=Anchor># </span>Pyoderma Gangrenosum in Ulcerative Colitis</h3></a><p><strong>Pyoderma gangrenosum involving the left leg. (Source: Pyoderma Gangrenosum in Ulcerative Colitis. N Engl J Med 2018.)</strong></p><a href=#aphthous-ulcers-of-the-palate-and-uvula-and-tongue><h3 id=aphthous-ulcers-of-the-palate-and-uvula-and-tongue><span class=hanchor arialabel=Anchor># </span>Aphthous Ulcers of the Palate and Uvula and Tongue</h3></a><p><strong>Aphthous ulcers (arrows) of the palate and uvula (U) and tongue (T). SP denotes soft palate. (Source: Manifestations of Crohn‚Äôs Disease ‚Äì Extraintestinal Manifestations of Crohn‚Äôs Disease. N Engl J Med 1994.)</strong></p><a href=#workup><h3 id=workup><span class=hanchor arialabel=Anchor># </span>Workup</h3></a><p>Diagnosis of IBD relies on the integration of history and clinical findings with investigational findings that include histopathology.</p><ul><li><p><strong>General laboratory investigations:</strong></p><ul><li><p>Albumin is usually reduced, and inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are typically raised during active disease.</p></li><li><p>If negative, fecal calprotectin may assist in precluding the need for further invasive investigation such as colonoscopy.¬†</p></li></ul></li><li><ul><li><p>Complete blood examination and iron studies may demonstrate anemia related to either iron deficiency or chronic disease and raised white cell count indicative of inflammation.</p></li><li><p>Stool examination: Fecal calprotectin is a neutrophil-derived protein biomarker that is a highly sensitive, noninvasive marker of intestinal inflammation.</p></li><li><p>Stool microscopy and culture evaluates for parasitic, viral, bacterial, and <em>Clostridiodes</em>¬†<em>difficile</em> infection.</p></li></ul></li><li><p><strong>Imaging:</strong> Magnetic resonance (MR) enterography or intestinal ultrasound (popular in Europe) can be used to assess for strictures and fistulae.</p></li><li><ul><li>MR enterography is recommended for all patients with new diagnosis of CD and required for monitoring if small-bowel disease is present.</li></ul></li><li><p><strong>Mucosal biopsy</strong> obtained during colonoscopy or upper endoscopy confirms the diagnosis in most cases of IBD if the duodenum is involved with CD.</p></li></ul><a href=#management><h3 id=management><span class=hanchor arialabel=Anchor># </span>Management</h3></a><p>IBD is a chronic disease that can have potentially devastating consequences for the patient and requires lifelong treatment. At each stage of disease, management requires careful consideration and tailoring to the individual patient. Broadly speaking, goals of treatment include:</p><ul><li><p>treating acute disease to reduce symptoms and preventing recurrences and complications</p></li><li><p>optimizing patient quality of life and correcting nutritional deficiencies</p></li><li><p>identifying patients who require early intensification of therapy due to risk of severe disease (e.g., age &lt;40 years, more-extensive disease)</p></li></ul><a href=#treatment><h3 id=treatment><span class=hanchor arialabel=Anchor># </span>Treatment</h3></a><p>Treatment of IBD includes aminosalicylates to reduce inflammation, immunosuppressive medications, biologic agents, and surgery. IBD treatment has two phases:</p><ol><li>induction of remission/treatment of flare</li><li>maintenance treatment</li></ol><p><strong>Induction of remission/treatment of flare:</strong></p><ul><li><p><strong>Crohn disease:</strong> Therapy involves a combination of glucocorticoids and immunosuppressive agents, with or without biologics.</p></li><li><p><strong>Ulcerative colitis:</strong> First-line induction therapy for mild-to-moderate disease is aminosalicylates (5-aminosalicylic acid [5-ASA], mesalamine, sulfasalazine). Topical aminosalicylic acid (ASA) is used primarily for proctitis or left-sided colitis. Short-term glucocorticoids and immunomodulators (e.g., thiopurines) are used for induction of more-severe disease. Biologic agents may also be used for more-severe disease.</p></li></ul><p><strong>Maintenance of disease remission:</strong></p><ul><li><p>Remission can be achieved with a combination of immunomodulators and biologics.</p></li><li><p>Avoid long-term glucocorticoid therapy due to high risk of complications.</p></li></ul><p><strong>Biologic therapy:</strong></p><ul><li><p>In the past three decades, biologic therapy has become a mainstay of treatment in high-risk patients with severe disease that is unresponsive to mesalamine or immunosuppressive drugs.</p></li><li><p>A number of biologic agents are available, and patients are typically maintained on a combination of biologic and immunomodulators for at least 12 to 18 months.</p></li><li><p>Due to the immunosuppressive effects of biologics, all patients need to be screened for latent tuberculosis (chest x-ray and interferon-gamma release assay) and hepatitis B status (hepatitis B surface antigen, hepatitis B core antibody, hepatitis B surface antibody) before commencing a biologic agent.</p></li></ul><a href=#biologic-agents-for-ibd><h3 id=biologic-agents-for-ibd><span class=hanchor arialabel=Anchor># </span>Biologic Agents for IBD</h3></a><table><thead><tr><th>Biologic Agent</th><th>Target of Action</th><th>Indication</th></tr></thead><tbody><tr><td>Infliximab</td><td>Tumor necrosis factor (TNF) inhibitor</td><td>CD and UC</td></tr><tr><td>Adalimumab</td><td>TNF inhibitor</td><td>CD and UC</td></tr><tr><td>Vedolizumab</td><td>Œ±4Œ≤7 integrin inhibitor (prevents lymphocyte migration into intestinal tissue)</td><td>CD and UC</td></tr><tr><td>Ustekinumab</td><td>Interleukin (IL)-12 and IL-23 antibodies</td><td>CD</td></tr><tr><td>Tofacitinib</td><td>Janus kinase (JAK) inhibitor, modulating cytokine signaling</td><td>UC (small effect in CD)</td></tr></tbody></table><p><strong>Surgery:</strong></p><ul><li><p><strong>Crohn disease:</strong> Approximately 50% of patients will need an operation to relieve a bowel obstruction or to treat fistulizing disease within the first 10 years of diagnosis. Surgery is not curative in CD; recurrence of symptoms and bowel inflammation is common within several years.</p></li><li><p><strong>Ulcerative colitis:</strong> Total colectomy is required in 15%‚Äì20% of patients. Surgery is curative in UC.</p></li></ul><p><strong>Monitoring:</strong></p><p>IBD can be associated with a range of complications, including colon cancer and increased risk of infection. As part of disease management, careful monitoring for complications is needed. Colonoscopies should be performed every 1 to 2 years to evaluate for signs of colon dysplasia, a precursor of colorectal cancer.</p><a href=#complications-of-ibd><h3 id=complications-of-ibd><span class=hanchor arialabel=Anchor># </span>Complications of IBD</h3></a><ul><li><p><strong>Crohn disease:</strong></p><ul><li><p>Small-bowel obstruction (SBO):</p><ul><li><p>SBO often results from strictures due to inflammation or adhesions from prior surgery, rarely from lymphoma.</p></li><li><p>Conservative management of SBO includes bowel rest, intravenous hydration, nasogastric tube decompression, and treatment of bowel inflammation.</p></li></ul></li><li><p>Perianal disease:</p><ul><li>Treatment includes antibiotics, systemic treatment of CD, and surgery to drain abscess or open fistula.</li></ul></li><li><p>Fistulas:</p><ul><li><p>Enterocutaneous fistulas (bowel-to-skin) may involve the abdominal wall or gluteal area.</p></li><li><p>Fistulas can also involve segments of intestine or between the bowel and urinary bladder, ureters, or vagina.</p></li><li><p>Management requires aggressive therapy for CD, usually with antibiotics.</p></li><li><p>Surgery may be required for chronic, nonhealing fistulas to divert the fecal stream and allow the intestine to heal and fistulas to close.</p></li></ul></li><li><p>Intra-abdominal abscess:</p><ul><li><p>These are often related to small, walled-off perforations or fistulizing CD.</p></li><li><p>Management involves antibiotics, interventional radiology‚Äìguided drainage, and stepped-up treatment of CD. Refractory cases may require surgery.</p></li></ul></li></ul></li></ul><a href=#intra-abdominal-abscess><h3 id=intra-abdominal-abscess><span class=hanchor arialabel=Anchor># </span>Intra-abdominal Abscess</h3></a><p><strong>A large abdominal-wall abscess with enterocutaneous fistulas (straight arrow)<br>(Source: Fistulizing Crohn‚Äôs Disease. N Engl J Med 2002.)</strong></p><ul><li><p><strong>Ulcerative colitis</strong>**:**</p><ul><li><p>Toxic megacolon (rare):</p><ul><li><p>Dilated colon can be seen on plain abdominal film or CT scan.</p></li><li><p>Treatment involves surgical consultation, nasogastric suction, intravenous (IV) antibiotics, fluid hydration, and anti-inflammatory drugs to reduce bowel inflammation.</p></li><li><p>If patients deteriorate or do not improve with conservative management, total colectomy is warranted to prevent perforation.</p></li></ul></li><li><p>Acute severe colitis:</p><ul><li>The severity of UC can be classified based on the Truelove and Witts criteria</li></ul></li></ul></li></ul><a href=#modified-truelove-and-witts-criteria-for-classification-of-acute-severe-colitis><h3 id=modified-truelove-and-witts-criteria-for-classification-of-acute-severe-colitis><span class=hanchor arialabel=Anchor># </span>Modified Truelove and Witts Criteria for Classification of Acute Severe Colitis</h3></a><table><thead><tr><th></th><th>Acute severe colitis</th></tr></thead><tbody><tr><td>Bloody stools per day</td><td>>6</td></tr><tr><td>Pulse</td><td>>90 beats/minute</td></tr><tr><td>Temperature</td><td>>37.8‚ÄÖ¬∞C (100¬∞F)</td></tr><tr><td>Hemoglobin</td><td>&lt;10.5 gm/dL</td></tr><tr><td>Erythrocyte sedimentation rate (ESR)</td><td></td></tr><tr><td>or</td><td></td></tr><tr><td>C-reactive protein (CRP)</td><td>>30 mm/hour</td></tr></tbody></table><blockquote><p>30 mg/dL |</p></blockquote><ul><li><ul><li><p>Management involves IV glucocorticoids and reassessment at day 3.</p></li><li><p>Patients who do not respond to treatment require rescue therapy (biologic) or colectomy.</p></li></ul></li><li><p>Primary sclerosing cholangitis (PSC):</p></li><li><ul><li><p>PSC affects approximately 5% of patients with UC and is more common in males; typical findings include extensive colitis, rectal sparing, and backwash ileitis.</p></li><li><p>Patients are often positive for antineutrophil cytoplasmic antibodies with cytoplasmic staining (c-ANCA).</p></li><li><p>PSC increases the risk for both colorectal cancer and cholangiocarcinoma.</p></li><li><p>The natural course of PSC is independent of IBD.</p></li><li><p>Treatment is discussed in the section on biliary disease.</p></li></ul></li><li><p><strong>Other complications of IBD:</strong></p></li><li><ul><li><p>Venous thromboembolism: Patients with IBD are at increased risk of deep-vein thrombosis and pulmonary embolism. All patients with IBD flares require chemoprophylaxis with subcutaneous or low-molecular-weight heparin.</p></li><li><p>Patients are at risk for malnutrition with nutritional deficiencies that can result in osteoporosis and peripheral neuropathy.</p></li><li><p>B-cell lymphomas have been independently associated with use of thiopurine and TNF inhibitors.</p></li><li><p>Colorectal cancer (CRC): Patients with long-standing colitis from CD or UC have 5 to 9 times higher risk of CRC than the general population and therefore require surveillance.</p><ul><li>The American Gastroenterological Association (AGA) and European Crohn‚Äôs and Colitis Organisation (ECCO) recommend¬†the following screening protocol for patients with IBD at risk of CRC:</li></ul></li></ul></li></ul><a href=#suggested-algorithm-for-colorectal-cancer-surveillance-in-inflammatory-bowel-disease><h3 id=suggested-algorithm-for-colorectal-cancer-surveillance-in-inflammatory-bowel-disease><span class=hanchor arialabel=Anchor># </span>Suggested Algorithm for Colorectal Cancer Surveillance in Inflammatory Bowel Disease</h3></a><p><strong>(Source: Cancers Complicating Inflammatory Bowel Disease. N Engl J Med 2015.)</strong></p><p><a class="internal-link broken">inbox</a></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>‚Ü©Ô∏è ÂèçÂêëÈÄ£Áµê</h3><ul class=backlinks><li><a href=/all-list-of-resident360/ data-ctx="Gastroenterology - Inflammatory Bowel Disease - Fast Facts  NEJM Resident 360" data-src=/all-list-of-resident360 class=internal-link>all list of resident360</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ü§Ø‰∫íÂãïÂúñ</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>Êú¨Á∂≤Á´ôÊòØÁî± Hsieh-Ting Lin ‰ª•‚ù§Ô∏è Áî® <a href=https://github.com/jackyzha0/quartz>Quartz</a>ÈÄôÂÄãÈÖ∑Êù±Ë•øÁ®ÆÂá∫‰æÜü™¥ , ¬© 2023</p><ul><li><a href=https://www.physician.tw/>üè†È¶ñÈ†Å</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>